Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling by van Eijl, Sven et al.
Elucidation of Xenobiotic Metabolism Pathways in
Human Skin and Human Skin Models by Proteomic
Profiling
Sven van Eijl1, Zheying Zhu1, John Cupitt1, Magdalena Gierula1, Christine Go¨tz2, Ellen Fritsche2,3,
Robert J. Edwards1*
1Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Imperial College London, London, United Kingdom, 2 Leibniz Institut fu¨r
Umweltmedizinische Forschung, Heinrich-Heine-Universita¨t, Du¨sseldorf, Germany, 3Department of Dermatology and Allergology, University Clinic RWTH, Aachen,
Germany
Abstract
Background: Human skin has the capacity to metabolise foreign chemicals (xenobiotics), but knowledge of the various
enzymes involved is incomplete. A broad-based unbiased proteomics approach was used to describe the profile of
xenobiotic metabolising enzymes present in human skin and hence indicate principal routes of metabolism of xenobiotic
compounds. Several in vitro models of human skin have been developed for the purpose of safety assessment of chemicals.
The suitability of these epidermal models for studies involving biotransformation was assessed by comparing their profiles
of xenobiotic metabolising enzymes with those of human skin.
Methodology/Principal Findings: Label-free proteomic analysis of whole human skin (10 donors) was applied and analysed
using custom-built PROTSIFT software. The results showed the presence of enzymes with a capacity for the metabolism of
alcohols through dehydrogenation, aldehydes through dehydrogenation and oxidation, amines through oxidation,
carbonyls through reduction, epoxides and carboxylesters through hydrolysis and, of many compounds, by conjugation to
glutathione. Whereas protein levels of these enzymes in skin were mostly just 4–10 fold lower than those in liver and
sufficient to support metabolism, the levels of cytochrome P450 enzymes were at least 300-fold lower indicating they play
no significant role. Four epidermal models of human skin had profiles very similar to one another and these overlapped
substantially with that of whole skin.
Conclusions/Significance: The proteomics profiling approach was successful in producing a comprehensive analysis of the
biotransformation characteristics of whole human skin and various in vitro skin models. The results show that skin contains a
range of defined enzymes capable of metabolising different classes of chemicals. The degree of similarity of the profiles of
the in vitro models indicates their suitability for epidermal toxicity testing. Overall, these results provide a rational basis for
explaining the fate of xenobiotics in skin and will aid chemical safety testing programmes.
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Introduction
Human skin is important as a passive physical barrier that
protects the body from the deleterious effects of noxious chemicals,
but it also protects the body in a more active fashion, through
enzymes that are present inside the skin. These xenobiotic
metabolising enzymes (XMEs) are located mostly in keratinocytes
within the epidermis, although levels are lower than those found in
liver [1,2]. Accurate detection and characterisation of the low
levels of skin XMEs has proved difficult and as a consequence
comprehensive information that describes the xenobiotic-metab-
olising capacity of skin is lacking [3].
Animals are widely used for the testing of new chemical entities,
and until recently these have included cosmetic ingredients that
have been tested for skin irritation, corrosion and genotoxicity.
However, under the 7th Amendment to the EU Cosmetics
Directive, which came into force in March 2009, animal testing of
cosmetic ingredients has been discontinued. As a result of this
there is a pressing need to develop ethically acceptable alternative
model systems that can be used to assess the safety of such
chemicals [4]. To this end, a number of artificial human skin
models have been developed for application as toxicity tests to
replace those that previously made use of animals for this purpose.
These include EpiDerm, a three-dimensional multilayered skin
culture derived from human neonatal foreskin keratinocytes,
Episkin, a reconstructed human epidermis model derived from
female adult keratinocytes from mammoplasty, and RHE, an in
vitro reconstructed human epidermis, consisting of normal human
keratinocytes derived from human neonatal foreskin. These three-
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dimensional models reproduce many of the characteristics of
normal human epidermis [5]. In addition, HaCaT cells, a
spontaneously immortalized male human keratinocyte cell line
[6], have been widely used for skin cytotoxicity and sensitization
testing [7,8]. Ideally, biotransformation of xenobiotics by these in
vitro models should mimic closely that which occurs in vivo,
although at present knowledge of the enzymes involved is far from
complete.
In this study, we set out to determine the XME profiles of whole
human skin (comprising both epidermis and dermis) and four in
vitro epidermal skin models of that are currently being used for
toxicity testing. The aim was to characterise the major pathways of
biotransformation present and to determine the consistency of the
XME profiles between the models.
Results
XMEs expression in whole human skin
Ten whole skin samples and 5 liver samples were analysed for
the presence of XMEs. Proteomic analysis was performed
separately on both microsomal and cytosol fractions and the data
combined. Overall, the proteomic analysis indicated the presence
of .2000 proteins in both skin and liver. PROTSIFT was used to
analyse these data and showed that whole skin contained 36
XMEs (Table 1). Almost all of these proteins were also found in
liver. The comparative levels in skin were mostly 4- 10 fold lower
than liver, although some enzymes were detected more readily in
skin (Table 1). Skin XMEs encompassed those with a variety of
functional processes including oxidoreduction, hydrolase, trans-
ferase and antioxidant. Many of these oxidoreduction enzymes are
responsible for the metabolism of alcohols, aldehydes and ketones.
The two hydrolase enzymes were detected in all skin samples
analysed. As for the transferases, several isoforms of glutathione S-
transferase (GST) were identified in skin. Apart from GST pi
which was ,2-fold higher than in liver, the levels were 2–8 fold
lower than those in liver. GST activity was measured in skin using
1-chloro-2,4-dinitrobenzene as a substrate and showed clearly
detected levels (91642 nmol/mg/min, n = 10), which were ,8-
fold higher in liver (7536134 nmol/mg/min, n= 5), and consis-
tent with the relative levels of the GST alpha, mu and omega
isoforms. Similarly, enzymes that function as antioxidants were
detected in the majority of skin samples analysed and present at
levels similar or slightly lower to those of liver.
The proteomics analysis also showed that liver contained an
additional 46 XMEs that were not detected in skin (Table 2). This
includes 13 CYP proteins encompassing all of the major forms
involved in xenobiotic metabolism. CYP1A2, CYP2E1 and
CYP3A4 could not be detected in skin under immunoblotting
conditions that readily showed their presence in human liver and
CYP1A1 could not be detected in either skin or liver, although a
preparation containing recombinant CYP1A1 was readily detect-
ed (Figure 1). The limit of detection of these CYP proteins by
immunoblotting is 2.5 pmol/mg microsomal protein (Figure S1).
Application of increased amounts of the respective antibodies used
for detection or increasing the development time only produced
non-specific bands without improving the detection of CYPs. The
protein loading of 75 mg used was the maximum amount possible
without causing problems with the electrophoretic separation of
the proteins. Further attempts were also made to detect CYP2B6,
CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in skin
samples using appropriate antibodies [9], but no specific
immunoreactive bands were detected (data not shown). Similarly,
no immunoreactive bands corresponding to any of these CYPs
were detected in any of the in vitro models tested. The low levels of
CYP proteins in skin was consistent with measurement of
ethoxyresorufin O-deethylase activity, which was ,0.1 pmol/
min/mg in skin microsomal fraction (below the limit of detection),
whereas the activity in human liver microsomal fraction was
39.5616.1 pmol/min/mg (n= 5).
Detection of CYP proteins in skin was investigated further by
estimating the limit of detection of CYP proteins by the proteomic
approach employed. Samples of skin microsomal fraction were
spiked with a range of concentrations of CYP1A1, CYP1A2,
CYP2E1, CYP3A4 and CYP3A5 and following the standard
proteomics workflow tryptic peptides corresponding to these CYP
proteins were identified and the limits of detection of each CYP
determined (Table 3). The values obtained are similar to those
determined previously for non-CYP proteins [10]. These values
were then used to calculate the limit of detection of each of the
CYP proteins in a 75 mg protein sample (the maximum that could
be separated by SDS-PAGE). On this basis the minimum amount
of CYP that can be detected in a sample by the procedure used
was found to be in the range of 0.1–0.2 pmol/mg microsomal
protein. Compared with average values measured in the micro-
somal fraction from a panel of donors it is apparent that the levels
in skin are at least 300-fold lower than that of liver (Table 3).
The proteomic approach also failed to detect any N-
acetyltransferase (NAT) isoform in skin or liver. This was despite
the ready detection of NAT activity using p-toluidene as substrate.
Samples of skin and liver cytosol contained 0.7–3.0 (range of 10
samples) [11] and 0.1–0.6 (range of 5 samples) nmol/min/mg
protein activity, respectively. Consequently, samples of skin cytosol
were spiked with a series of amounts of recombinant NAT1 and
the proteomics analysis performed to determine a limit of
detection for this protein. This was found to be 3 pmol/mg
cytosolic protein.
XME expression in skin models
XME profiles of RHE, HaCaT cells, EpiSkin and 2 different
donors (254 and 1188) of the Epiderm-200 model were
determined by proteomics. The number of unique tryptic peptides
detected for each protein by liquid chromatography-tandem mass
spectroscopy (LC-MS/MS) was used as an indirect measure of the
relative quantity of each protein (Figure 2). Overall the profiles of
expression of XMEs amongst the models are very similar. The
majority of the XMEs present in the in vitro models were also
present in whole human skin (Figure 2). However, some XMEs
that were readily detected in whole skin were not detected in the in
vitro model cells including epoxide hydrolase 1, liver carboxyles-
terase 1, alcohol dehydrogenase 1B and 4, aldehyde dehydroge-
nase 1L1, membrane primary amine oxidase, amine oxidase B,
aldehyde oxidase and GST theta (Figure 2). On the other hand
some proteins were detected in all or most of the in vitro models
that were not detected in whole skin, including aldehyde
dehydrogenase 7A1, NADPH-cytochrome P450 reductase and
sulfotransferase 2B1 (Figure 2).
Stability of XME expression during culture of the
EpiDerm-200 model
The Epiderm-200 model is often used for genotoxicity studies
[12] and such assessments are typically performed over several
days. In order to determine whether the profile of XMEs varies
over the course of such prolonged incubations, Epiderm-200
derived from two donors (254 and 1188) were cultured for up to 3
days, sampling at 1 day intervals. On the basis of the number of
unique tryptic peptides detected for each protein, the results show
that, with just a few exceptions, the detected XMEs were present
Xenobiotic Metabolising Enzymes in Human Skin
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Table 1. XMEs detected in whole skin. Protein identification was based on the presence of $2 different tryptic peptides in at least
two donors.
Detection rate
(% of samples) Relative level
Protein NCBI number Fraction Skin Liver skin/liver p-value
OXIDOREDUCTASE
3-hydroxyacyl-CoA dehydrogenase type-2 NP_004484.1, NP_001032900.1 cytosol 80 100 0.10 ,0.001
alcohol dehydrogenase 1B NP_000659.2 cytosol 100 100 0.25 ,0.001
alcohol dehydrogenase 4 NP_000661.2 cytosol 30 100 0.23 ,0.001
alcohol dehydrogenase class-3 NP_000662.3 cytosol 30 20 0.67 0.31
aldehyde dehydrogenase 1A1 NP_000680.2 cytosol 70 100 0.13 ,0.001
aldehyde dehydrogenase 1L1 NP_036322.2 cytosol 20 100 0.08 ,0.001
aldehyde dehydrogenase 2 NP_000681.2 microsome 100 100 0.07 ,0.001
aldehyde dehydrogenase 3A2 NP_001026976.1, NP_000373.1 microsome 40 100 0.07 ,0.001
aldehyde dehydrogenase 9A1 NP_000687.3 cytosol 50 100 0.39 ,0.001
aldehyde oxidase NP_001150.3 cytosol 30 100 0.26 ,0.001
aldo-keto reductase 1A1 NP_697021.1, NP_006057.1 cytosol 100 100 0.06 ,0.001
aldo-keto reductase 1C NP_001809.2, NP_995317.1, NP_001128713.1,
NP_001345.1, NP_001344.2, NP_003730.4
cytosol 100 100 0.04 ,0.001
amine oxidase [flavin-containing] B NP_000889.3 microsome 80 100 0.03 ,0.001
carbonyl reductase [NADPH] 1 NP_001748.1 cytosol 100 100 0.11 ,0.001
carbonyl reductase [NADPH] 3 NP_001227.1 cytosol 70 100 0.17 ,0.001
membrane primary amine oxidase NP_003725.1 microsome 90 0 .6.7 ,0.001
NADH-ubiquinone oxidoreductase NP_004997.4 microsome 100 100 1.11 0.51
prostacyclin synthase NP_000952.1 microsome 90 0 .1.7 ,0.001
short-chain dehydrogenase/reductase 7 NP_057113.1, NP_001099041.1, NP_056325.2 microsome 70 100 0.21 ,0.05
HYDROLYASE
epoxide hydrolase 1 NP_001129490.1, NP_000111.1 microsome 100 100 0.10 ,0.001
liver carboxylesterase 1 NP_057113.1, NP_001099041.1, NP_056325.2 microsome 100 100 0.62 0.21
TRANSFERASE
gamma-glutamyltransferase 5 NP_001093252.1, NP_004112.2, NP_001093251.1 microsome 100 40 1.20 0.31
glutathione S-transferase alpha NP_665683.1, NP_001503.1, NP_714543.1,
NP_000837.3, NP_000838.3
cytosol 50 100 0.12 ,0.001
glutathione S-transferase mu NP_671489.1, NP_001135840.1, NP_666533.1, NP_000552.2,
NP_000840.2, NP_000842.2, NP_000841.1, NP_000839.1
cytosol 100 100 0.17 ,0.001
glutathione S-transferase omega NP_899062.1, NP_004823.1 cytosol 40 100 0.12 ,0.001
glutathione S-transferase pi NP_000843.1 cytosol 100 100 1.97 ,0.05
glutathione S-transferase theta NP_000845.1, NP_001074312.1, NP_000844.2 cytosol 50 100 0.57 ,0.05
ANTIOXIDANT
catalase NP_001743.1 cytosol 90 100 0.24 ,0.001
glutathione peroxidase 3 NP_002075.2 cytosol 100 0 .1.2 ,0.001
peroxiredoxin-1 NP_002565.1, NP_859047.1, NP_859048.1 cytosol 100 100 0.21 ,0.001
peroxiredoxin-2 NP_005800.3, NP_859428.1 cytosol 100 100 0.84 0.51
peroxiredoxin-5 NP_857635.1, NP_857634.1, NP_036226.1 cytosol 70 100 0.25 ,0.001
peroxiredoxin-6 NP_004896.1 cytosol 100 100 0.05 ,0.001
OTHER
14-3-3 protein beta/alpha NP_003395.1, NP_647539.1 cytosol 100 100 1.56 ,0.05
glyceraldehyde-3-phosphate dehydrogenase NP_002037.2 cytosol 100 100 0.82 0.51
long chain fatty acid-CoA ligase 1 NP_004449.1, NP_055977.3, NP_001986.2 microsome 60 100 0.03 ,0.001
The proteins identified have been classified into functional groups as indicated. The corresponding NCBI numbers are indicated for each protein and for all members of
groups of related proteins. The sub-cellular fraction in which each protein was principally detected is shown. The proportion of donor samples (skin n = 10, liver n = 5) in
which each protein was identified is indicated. Fold difference was calculated by summing the intensity values of all detected peptides for a protein and comparing the
values obtained for skin and liver. Where no peptides were detected, an intensity value equivalent to the limit of detection was used. Statistical significance was
assessed using the Mann-Whitney U test.
doi:10.1371/journal.pone.0041721.t001
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at similar levels over incubation times of up to 3 days in both
EpiDerm-200 models (Figure 3).
Discussion
To our knowledge, this is the first study to offer a comprehen-
sive overview of protein expression profiles of XMEs in human
skin and in vitro skin models. To generate these data, a process by
which proteomic data is analysed was devised to produce a defined
and transparent (non-subjective) method by which XMEs were
identified. As the identification is based on an inclusion and
exclusion keyword list, the approach can be modified easily to
identify other groups of proteins. The use of the PROTSIFT
software allows the major part of the data analysis to take place in
an automated fashion, minimizing human error and enabling easy
re-analysis of large mass spectrometry datasets using different
criteria to explore the data. The approach relies on the accuracy of
the keywords used to extract data from the proteins of relevance,
in this case to those involved in the biotransformation of
chemicals. In an attempt to capture all relevant information a
list of inclusion keywords were derived from gene ontology
annotation data sources for positive identification of XMEs and to
reduce the number of falsely assigned proteins an exclusion
keyword list was also utilised. Overall, the majority of the proteins
identified in this way appeared to have a clear function in chemical
biotransformation, although the process is limited by the extent of
current knowledge and the lack of a clear definition an XME.
Nevertheless, the process may be further refined to include or
exclude proteins based on further or more specific knowledge of
the function of the proteins involved.
Overall the profile of detected XMEs in skin indicates a capacity
for the phase I metabolism of alcohols through dehydrogenation,
aldehydes through dehydrogenation and oxidation, amines
through oxidation, carbonyls through reduction, and epoxides
and carboxylesters through hydrolysis, whereas phase II metab-
olism is represented by several forms of GST. Examples of
compounds metabolised this way in human skin include aliphatic
alcohols [13], cinnamaldehyde, cinnamic alcohol [14], 5-hydroxy-
tryptamine [15], capsaicin [16], betamethasone 17-valerate and
propranolol [17]. Skin also appears to possess an antioxidant
capacity as it contains catalase, glutathione peroxidase 3 and
several peroxiredoxin forms. Overall, whole skin contains a
reasonable diversity of XMEs that facilitate a range of biotrans-
formation reactions (Figure 4). Almost all of the XMEs detected in
skin are also present in liver. In general the relative levels are
higher in liver and liver contains more XMEs in each class. Thus,
the routes of metabolism in skin are likely to be more limited than
those that occur in liver. There were exceptions to this as skin
contained some proteins that were not detected in liver, including
prostacyclin synthase (CYP8), and membrane primary amine
oxidase, as well as some other proteins, such as alcohol
dehydrogenase class-3 and GST pi, that were expressed at similar
or greater levels in skin compared to liver. GST pi has been shown
to be the predominant form of GST in epidermis [18] but not in
the liver, where the alpha and mu gene families are highly
expressed [19].
Many of the XMEs in skin identified at the protein level have
also been identified at the RNA level. If an arbitrary threshold of
200,000 copies per mg RNA is considered then almost all of the
gene products found in a study of human whole skin are
represented here as proteins [20]. Similarly, those gene products
detected above a signal intensity threshold value of 10,000 in a
microarray approach to examine expression in whole skin [21] are
consistent with the proteins identified in this present study.
Support for the identification of alcohol/aldehyde dehydrogenase
and esterase enzymes is from enzyme activity assays performed on
whole human skin [3]. These workers also detected sulfotransfer-
ase activity, whereas the proteomics approach used here failed to
detect such an enzyme in whole skin although detection was
evident in the in vitro models.
CYP enzymes in families 1–3 metabolise xenobiotics and none
of these were detected in whole skin or any of the in vitro skin
models of skin by either proteomics or immunoblotting. This
contrasts with liver where 13 CYP XMEs, encompassing all of the
major forms involved in xenobiotic metabolism, were detected by
proteomics and by immunochemical methods [9]. These results
are quite different from those found in rat skin where expression of
several CYP proteins was evident [22]. There have been a number
of publications that claim the presence of various members of the
CYP1, CYP2 and CYP3 families in skin, some on the basis of gene
expression and others by immunochemical detection of the
proteins [1]; [2]; [23]; [24]; [24]. The use of PCR to detect
mRNA species is very sensitive but the relationship of low mRNA
levels to CYP protein expression levels is uncertain (e.g. [25]),
although, as described above, when quantified, low RNA levels in
skin appear to correspond to low levels of protein expression.
Immunochemical methods of detection are dependent on both the
Figure 1. Analysis of CYP expression in skin by immunoblot-
ting. Samples of human whole skin microsomal fraction (75 mg)
prepared from 5 donors were separated by SDS-PAGE, transferred to
nitrocellulose filters and the presence of CYP1A1, CYP1A2, CYP2E1 and
CYP3A4 detected using antibodies specific to each form. The lane on
the left hand side contained either 25 mg lymphoblast cell microsomes
containing recombinant human CYP1A1 (,2 pmol), or a sample of
human liver loaded with 25, 35 or 5 mg microsomal fraction for
detection of CYP1A2, CYP2E1, or CYP3A4, respectively. Immunoreactive
bands were developed using goat anti-rabbit-horseradish peroxidase
and ECL detection.
doi:10.1371/journal.pone.0041721.g001
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Table 2. XMEs detected in liver but not detected in whole skin. Protein identification was based on the presence of $2 different
tryptic peptides.
Protein NCBI number Fraction Detection rate (% of samples)
OXIDOREDUCTASE
alcohol dehydrogenase 1A NP_000658.1 cytosol 100
alcohol dehydrogenase 1C NP_000660.1 cytosol 100
alcohol dehydrogenase 6 NP_001095940.1, NP_000663.1 cytosol 100
aldehyde dehydrogenase 7A1 NP_001173.2 cytosol 100
aldehyde dehydrogenase 8A1 NP_739577.1, NP_072090.1 cytosol 100
aldehyde dehydrogenase X NP_000683.3 cytosol 100
amine oxidase [flavin-containing] A NP_000231.1 microsome 100
carbonyl reductase 4 NP_116172.2 cytosol 40
cytochrome P450 1A2 NP_000752.2 microsome 100
cytochrome P450 2A6/2A7/2A13 NP_000753.3, NP_000755.2,
NP_000757.2, NP_085079.2
microsome 100
cytochrome P450 2B6 NP_000758.1 microsome 80
cytochrome P450 2C19 NP_000760.1 microsome 100
cytochrome P450 2C8 NP_000761.3 microsome 100
cytochrome P450 2C9 NP_000762.2 microsome 100
cytochrome P450 2D6 NP_001020332.1, NP_000097.2 microsome 100
cytochrome P450 2E1 NP_000764.1 microsome 100
cytochrome P450 2J2 NP_000766.2 microsome 40
cytochrome P450 3A4 NP_073731.1, NP_476437.1,
NP_476436.1, NP_059488.2
microsome 100
cytochrome P450 3A5 NP_000768.1 microsome 40
cytochrome P450 4A11 NP_000769.2 microsome 100
cytochrome P450 4F12 NP_076433.2 microsome 100
dimethylaniline monooxygenase [N-oxide-forming] 3 NP_001002294.1, NP_008825.4 microsome 100
dimethylaniline monooxygenase [N-oxide-forming] 5 NP_001138301.1, NP_001452.2 microsome 100
electron transfer flavoprotein-ubiquinone oxidoreductase NP_004444.2 microsome 100
kynurenine 3-monooxygenase NP_003670.2 microsome 100
methylmalonate-semialdehyde dehydrogenase [acylating] NP_005580.1 cytosol 100
NADPH-cytochrome P450 reductase NP_000932.3 microsome 100
succinate-semialdehyde dehydrogenase NP_733936.1, NP_001071.1 cytosol 100
sulfide:quinone oxidoreductase NP_067022.1 microsome 100
xanthine dehydrogenase/oxidase NP_000370.2 cytosol 100
HYDROLYSIS
carboxylesterase 2 NP_003860.2, NP_932327.1 microsome 100
epoxide hydrolase 2 NP_001970.2 cytosol 100
TRANSFERASE
bile salt sulfotransferase NP_003158.2 cytosol 100
glutathione S-transferase kappa NP_001137151.1, NP_001137153.1,
NP_001137152.1, NP_057001.1
cytosol 100
glutathione S-transferase zeta NP_665877.1, NP_665878.2,
NP_001504.2
cytosol 100
histamine N-methyltransferase NP_001019246.1, NP_001019245.1,
NP_008826.1
cytosol 40
microsomal glutathione S-transferase 1 NP_665734.1, NP_665735.1,
NP_064696.1, NP_665707.1
microsome 100
nicotinamide N-methyltransferase NP_006160.1 cytosol 100
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method and the properties of the antibody used, particularly with
respect to its specificity and sensitivity. It is possible that some of
the previous results may be explained by the use of antibodies with
markedly superior sensitivity. However, this does not seem likely,
and as none of the previous studies indicate the sensitivity of the
immunochemical methods used it is not possible to compare those
results with this current study, nevertheless, under the conditions
specified here, the LC-MS/MS method applied is about 25-times
more sensitive than immunoblotting and the specificity is assured
by the MS identification of characteristic tryptic peptides. Based
on the limit of detection of CYPs by LC-MS/MS of 0.1 pmol/mg
microsomal protein it is possible to make an assessment of the
likely relative capacity of skin to perform CYP-catalysed reactions
compared with liver and hence place the results in some rational
context. The finding that skin CYP levels are at least 300-fold
lower than those of liver indicates that the rate of oxidative
biotransformation of a xenobiotic catalysed by any CYP enzyme
present will be very low, limiting its contribution to overall dermal
metabolism.
The lack of detection of NAT in skin by proteomics is perhaps
surprising, although this is consistent with the levels of NAT1 and
NAT2 mRNA which have been found to be very low or
undetectable in human epidermis and dermis [20]. A previous
study has determined that the specific activity of pure recombinant
human NAT1 is 254 mmol/min/mg NAT1 (i.e. 8.62 nmol/min/
pmol NAT1) using p-amino benzoic acid as substrate [26]. On this
basis the limit of detection possible by proteomics of 3 pmol
NAT1/mg cytosolic protein equates to an activity of ,25 nmol/
min/mg cytosolic protein and this value exceeds that of skin
cytosol and liver cytosol by approximately 3- or 10-fold,
respectively [27,28]. Thus, measurements of NAT levels by
enzyme activity are more sensitive than the proteomics approach
used here.
The proteomics approach is limited by the ability to detect a
sufficient number of tryptic peptides derived from each protein.
Digestion of a single protein with trypsin will yield many peptides,
the number being proportional to the size of the protein and the
frequency of occurrence of trypsin-sensitive sites. The detection of
peptides by LC-MS is dependent on the size of the peptides, their
ionisation in the electrospray, separation by LC, and both the
resolution and sensitivity on the MS used. Thus, not all tryptic
peptides will be identified and indeed it is generally sufficient if just
two peptides can be clearly identified provided adequate
fragmentation data can be obtained and the peptides identified
occur in just one protein. Nevertheless, in cases where more
peptides are identified, this indicates not only a greater abundance
Table 2. Cont.
Protein NCBI number Fraction Detection rate (% of samples)
thiosulfate sulfurtransferase NP_003303.2 cytosol 100
STEROID METABOLISM
11-beta-hydroxysteroid dehydrogenase 1 NP_005516.1, NP_861420.1 microsome 100
17-beta-hydroxysteroid dehydrogenase 13 NP_835236.2, NP_001129702.1 microsome 100
17-beta-hydroxysteroid dehydrogenase type 6 NP_003716.2 microsome 100
hydroxysteroid dehydrogenase like 2 NP_115679.2 cytosol 80
OTHERS
catechol O-methyltransferase NP_000745.1, NP_009294.1,
NP_001128633.1, NP_001128634.1
cytosol 100
gamma-glutamyl carboxylase NP_001135741.1, NP_000812.2 microsome 80
glutamate-cysteine ligase catalytic subunit NP_001489.1 cytosol 40
The proteins identified have been classified into functional groups. The corresponding NCBI numbers are indicated for each protein and for all members of groups of
related proteins. The sub-cellular fraction in which they were principally detected is shown. The proportion of liver samples (n = 5) in which each protein was identified is
indicated.
doi:10.1371/journal.pone.0041721.t002
Table 3. Detection of CYP proteins in skin and liver microsomal fraction by LC-MS/MS.
Limit of detection (fmol) Microsomal level (pmol/mg) Relative level in skin compared with liver
Protein Skin Liver
CYP1A1 1.5 ,0.11 ,0.11 n/a
CYP1A2 2.0 ,0.16 50 ,0.003
CYP2E1 1.5 ,0.11 35 ,0.003
CYP3A4 3.0 ,0.23 105 ,0.002
CYP3A5 1.0 ,0.08 25 ,0.003
Samples of skin microsomal fraction were spiked with a range of quantities of either recombinant CYP1A1 (expressed in lymphoblast cells) or with human liver
microsomal fraction that contains known amounts of CYP1A2, CYP2E1, CYP3A4, and CYP3A5. The normal proteomics workflow was followed to identify peptides
corresponding to the CYP proteins. Limits of detection based on the use of at least 2 tryptic peptides were established and based on these values the minimum level
detectable by this technique was calculated for skin and compared with the mean level measured in liver. From these values the minimum comparative level in skin was
calculated. CYP1A1 was not detected in either skin or liver making any comparison redundant (n/a; not applicable).
doi:10.1371/journal.pone.0041721.t003
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of a protein but also leads to an improved certainty of the
identification of that protein. Relative label-free quantification, as
used here, is based on the same criteria of identification and utilises
peptide ion intensity to compare levels, thus those peptides that
ionise well provide the clearest data and as we and others have
shown previously the relationship between ion intensity and
Figure 2. Comparison of XME profiles from in vitro skin models and whole skin. The relative amount of each protein is represented by the
number of different tryptic peptides specific to each protein or protein family that were detected. Details of the protein accession numbers and their
subcellular location are shown in Table S1. Shading indicates different enzyme classes: oxidoreductase (black), hydrolase (magenta), transferase (red),
antioxidant (green), and other (blue).
doi:10.1371/journal.pone.0041721.g002
Figure 3. Stability of Epiderm-200 XME expression profiles in culture. Epiderm-200 cultures were derived from either donor 254 or 1188 and
were maintained for up to 3 days. The relative amount of each protein is indicated by the number of different tryptic peptides specific to each protein
or protein family that were detected with adjacent bars representing results from 0, 1, 2 and 3 days, respectively. Details of the protein accession
numbers and their subcellular location are shown in Table S2. Shading indicates different enzyme classes: oxidoreductase (black), transferase (red),
antioxidant (green), and other (blue).
doi:10.1371/journal.pone.0041721.g003
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quantity holds for up to a range of 3-orders of magnitude [10]. As
with all methods, the current approach is limited in its sensitivity.
Improved sensitivity could be obtained by the use of an MS with
better inherent resolution and accuracy and also by the use of MS
methods with improved quantitative capacity such as multiple
reaction monitoring [29]. It is possible that with the application of
such methods and/or superior instrumentation that the levels of
CYP and NAT proteins in skin samples may be detected and
quantified.
The XME profiles of the in vitro skin models were similar to one
another, suggesting that many biotransformation pathways are
comparable. A number of XMEs that were identified in whole
human skin were not detected in the in vitro models. Lower levels of
mRNA encoding for several XMEs including epoxide hydrolase 1
have been found in the epidermis compared with the dermis [20].
It is possible therefore that the in vitro skin models which are
epidermal in origin may contain lower levels of some XMEs.
Interestingly though, the in vitro models contain some important
enzymes including NADPH-cytochrome P450 reductase, aldehyde
dehydrogenase 7A1 and sulfur transferase enzymes that were not
detected in whole skin. This may be due to the culture conditions
in which the models were maintained. Sulfotransferase 2B1b has
been shown to be expressed at higher levels in normal human
epidermal keratinocytes after culture, especially when the medium
contains increased levels of calcium [30]. The stability of XME
expression profiles of both Epiderm-200 models were examined
and found to be similar for incubation times of up to 3 days. The
main exception to this was NADPH-cytochrome P450 reductase,
which was readily detected in both models on day 0, but levels
decreased during culture until by 3 days was undetectable. Overall
though, the profiles appeared relatively stable, suggesting their
suitability for studies requiring longer culture times.
In conclusion, a proteomics approach has been successfully
applied to make a comprehensive analysis of the biotransformation
characteristics of whole human skin and various in vitro skin
models. The results indicate that skin contains a range of XMEs
capable of metabolising a variety of classes of chemicals. However,
the capacity for CYP-mediated metabolism of xenobiotics in skin
appears to be very low in comparison with liver. The various in
vitro models of human skin examined had profiles similar to one
another and to that of whole skin. In the case of the EpiDerm
models the levels of enzymes remained stable for at least 3 days,
supporting their suitability in tests that require relatively long
exposure times, such as those used for the assessment of
genotoxicity. Overall, these data should help in the development
of a rational basis for understanding the fate of xenobiotics in skin.
Materials and Methods
Sample preparation
Samples of human whole skin were obtained from healthy
females undergoing reduction mammoplasty (n = 10) at the
Kaiserswerther Diakonie hospital in Du¨sseldorf, Germany. The
mean age was 44613 years. During the procedure patients were
sedated with propofol and/or remifentanil; none were receiving
regular medication. Patients gave their written consent for the
excess skin removed to be used for scientific research purposes and
the project, which followed the Declaration of Helsinki protocols,
was approved by the Ethickkommission der Medizinischen
Fakulta¨t der Heinrich-Heine-Universita¨t, Du¨sseldorf. Skin samples
were collected immediately following surgery, chilled on ice during
transportation to the laboratory and then stored at 280uC until
processed. Subcutaneous tissue was carefully removed before skin
samples were cut into small pieces, and then homogenized (SW18,
Ultra-Turrax, Germany) in 1.5-volumes of ice-cold 250 mM
potassium phosphate buffer, pH 7.25 containing 150 mM KCl
and 1 mM EDTA. Microsomal and cytosol fractions were
prepared by differential centrifugation as described previously
[31] and stored at 280uC until required. Human liver microsomal
and cytosolic fractions had been prepared previously and stored at
Figure 4.Potential routes of xenobiotic metabolism in skin and liver. The size of each arrow is proportional to the number of XMEs detected
that may catalyse each bioconversion indicated.
doi:10.1371/journal.pone.0041721.g004
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280uC [9]. Epiderm-200 (MatTek Corporation, Ashland, MA,
USA), RHE (SkinEthic Laboratories, Lyon, France), and EpiSkin
(SkinEthic Laboratories) were cultured using the medium provided
by the respective manufacturer until analysis. The stability of
XME expression in Epiderm-200 was determined after the normal
procedure to establish the 3-dimensional cultures and then after
culture for 1, 2 and 3 days; in these experiments the medium was
replaced daily. HaCaT cells (German Cancer Research Center,
Heidelberg, Germany) were cultured in T75 flasks at 37uC with
5% CO2 in DMEM supplemented with 10% fetal bovine serum,
100 IU penicillin/streptomycin and 2 mM glutamine. The
medium was changed every 3 days and cells were sub-cultured
when confluent. The cultures were washed with PBS before being
homogenized and subcellular fractions prepared as described for
human skin.
Immunoblotting and CYP content
Immunoblotting was performed using up to 75 mg of micro-
somal protein and rabbit antibodies targeted against either
CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C forms, CYP2D6,
CYP2E1, CYP3A4, CYP3A5, or CYP4A11, as described previ-
ously [9]. A preparation of recombinant CYP1A1 protein
expressed in insect cell microsomal fraction was purchased from
Gentest BD (Franklin Lakes, NJ USA). Estimation of the
apoprotein content of CYP1A1, CYP1A2, CYP2E1, CYP3A4
and CYP3A5 was determined immunochemically using synthetic
peptides as standards as described previously [32]. The limit of
detection by immunoblotting was determined as described in the
Figure S1.
Enzyme activity assays
Ethoxyresorufin O-deethylase activity was determined as
described previously [33]. The assay mixture contained 2 mM
ethoxyresorufin and 5% final concentration of microsomal
protein. NAT activity was estimated using p-toluidene as substrate
as described previously [11]. GST activity was measured
according to an established protocol using 1-chloro-2,4-dinitro-
benzene as the substrate [34].
Proteomics
The workflow employed is summarized in figure 5. The protein
content of all samples was estimated using the bicinchoninic acid
method (Thermo Fischer Scientific, Cramlington, UK) with
bovine albumin as the calibration standard. Proteins in micro-
somal and cytosol fractions from skin, skin models and liver
samples were separated using 10% NuPAGE Novex bis-tris gels
(Invitrogen Ltd., Paisley, UK). Gels were stained with Instant-
BlueH and each sample-containing lane cut into a series of 20
regions based on the position of molecular weight markers
(SeaBlue MarkerH, Invitrogen Ltd., Paisley, UK) and the
distribution of proteins observed in the gel. Each gel piece was
then digested with trypsin, peptides extracted and dried. Dried
samples were reconstituted, injected onto a reverse phase column
and the eluted peptides analysed by liquid chromatography
tandem mass spectrometry on-line using an Agilent 1200 LC
series (Agilent Technologies UK Ltd., Berkshire, UK) and a
Thermo LTQ linear ion trap MS (Thermo Scientific, Hemel
Hempstead, UK) as described previously [35].
Data analysis was performed essentially as described previously
[35] with some modifications. Analysis was restricted to those
proteins with a putative role in xenobiotic metabolism and these
were selected in an automated fashion using PROTSIFT (https://
github.com/jcupitt/protsift), which is software that was written for
this purpose to allow application of a transparent procedure. In the
process protein names containing the word ‘hypothetical’ or ‘like’
were filtered out automatically. The selection of proteins as
putative XMEs also took place in an automated fashion, based on
a keyword list search. To assemble the keyword list, a number of
sources were used. Relevant enzyme category names were taken
from [36] and combined with the results of a search on the
AmiGO website (http://amigo.geneontology.org) for gene prod-
uct associations to the term ‘‘xenobiotic metabolic process’’ (GO
term 0006805). Also, gene products referred to in some recent
studies examining XME expression at the RNA level [20,21] were
included. Proteins that were obviously not involved in xenobiotic
metabolism were eliminated by use of a reject list to give a final list
of putative XME proteins.
The PROTSIFT enzyme accept list comprised: 3-Hydroxyacyl-
CoA dehydrogenase, acyl-coenzyme A synthetase ACSM1,
adrenodoxin, alcohol dehydrogenase, aldehyde dehydrogenase,
aldehyde oxidase, aldo-keto reductase, amine oxidase, arylaceta-
mide deacetylase-like 1, bifunctional 39-phosphoadenosine 59-
phosphosulfate synthase, carbonyl reductase, carboxylesterase,
catalase, catechol-O-methyltransferase, catechol O-methyltrans-
ferase, cytochrome P450, dehydrogenase/reductase SDR family
member, dopamine beta-hydroxylase, epoxide hydrolase, gamma-
glutamyl carboxylase, gamma-glutamyltranspeptidase, glucuroni-
dase, glutamate–cysteine ligase, glutathione peroxidase, glutathi-
one transferase, glutathione synthetase, hepatocyte nuclear factor
4-alpha, histamine N-methyltransferase, hydroxysteroid dehydro-
genase, kynureninase, lactoperoxidase, long-chain-fatty-acid–CoA
ligase 1, monooxygenase, N-acetyltransferase, NAD\(P\)H dehy-
drogenase \[quinone\] 1, NAD(P) transhydrogenase, mitochon-
drial, nicotinamide N-methyltransferase, nitric oxide synthase,
nuclear receptor subfamily 1 group I member 2, peroxiredoxin,
prostaglandin G/H synthase, prostacyclin synthase, protein S100-
A12, quinone oxidoreductase, steryl-sulfatase, sulfotransferase,
thiopurine S-methyltransferase, thiosulfate sulfurtransferase, thy-
roid peroxidase, trans-1,2-dihydrobenzene-1,2-diol dehydroge-
nase, thromboxane-A synthase, and xanthine dehydrogenase.
The PROTSIFT enzyme reject list comprised: carbohydrate,
heparan, glucose-6-phosphate dehydrogenase, protein-glutamine
gamma-glutamyltransferase, and dolichyl-diphosphooligosacchar-
ide-protein glycosyltransferase.
Application of the keyword search of the whole human RefSeq
database (version 38) resulted in a list of 443 proteins identified as
potential XMEs from a total number of proteins of 38,783. These
proteins are listed in Table S3.
The issue of redundancy in identified proteins was addressed by
including all possible assignments in the primary results table. The
peptides used to identify each protein were then examined to
determine if they occurred in the sequence of any other protein in
the database and these occurrences were also listed. The
uniqueness (or otherwise) of the assignment of peptides to the
sequence of one or more proteins was used to determine whether
an assignment could be made to a specific protein or to a group of
related proteins (such as isoforms). Where it was not possible to
distinguish between related proteins from tryptic peptide data due
to their close structural identity the data has been consolidated into
a root description of the protein e.g. data from peptides
overlapping in their assignment to one or more of the GST alpha
isoforms 1, 2, 3 and 5 have been combined and the assignment
reported as GST alpha. Hence proteins may be represented by a
single accession number or a series of accession numbers. For
proteins detected in more than one gel region, only data from the
region that contained the greatest number of detected peptides for
each protein was considered. Data from cytosolic and microsomal
fractions were combined. Where proteins were found in both
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Figure 5. Flow diagram summarizing the methodology.
doi:10.1371/journal.pone.0041721.g005
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fractions, the fraction in which the protein was most readily
detected is reported. When similar levels were detected in both
fractions, and their location as such was confirmed using Uniprot
(uniprot.org), both are reported. Details of the peptides detected
for each protein are listing in the Table S4.
In some cases, limits of detection of proteins were determined by
spiking samples of microsomal fraction or cytosol with recombi-
nant CYPs (Gentest BD) or NAT1 with an N-terminal GST tag
(Abnova, Taipei, Taiwan).
Statistical analyses
Fold difference values were calculated on the basis of the
summed ion intensities of the component peptides, using DeCyder
MS (Version 2.0, GE Healthcare Biosciensces, Uppsala, Sweden)
software. Statistical significance was determined by the Mann-
Whitney U-test, using GraphPad Prism (version 4.00 for Windows,
GraphPad Software, San Diego, California, USA).
Supporting Information
Figure S1 Examples of quantitation of CYP enzymes by
immunoblotting. In each case, respective synthetic peptide
(coupled to lysozyme) or recombinant protein antigen was loaded
onto SDS-polyacrylamide gels in quantities of up to 10 pmol and
developed with rabbit antibodies raised against synthetic peptides
corresponding to each of the CYP enzymes that were first
immunodepleted of antibodies against carrier protein and
coupling linkage as described previously [37]. Immunoreactivity
was detected using a goat anti-rabbit IgG-horseradish peroxidase
and visualised by enhanced chemiluminescence that was recorded
on Hyperfilm and analysed using a Kodak Image Station as
indicated in the Methods section. Each point represents the mean
and SEM of at least 4 determinations. The relationship between
the quantity loaded and the intensity of immunoreactivity and was
reasonably linear for loadings of up to 1 pmol antigen but
flattened with greater quantities. The least amount of antigen that
could be detected was typically 0.2 pmol, which is equivalent to
2.5 pmol/mg microsomal protein for a sample loading of 75 mg
microsomal protein.
(TIF)
Table S1 Details of XME proteins detected in whole
skin and in vitro skin models. NCBI numbers for each
protein and for all members of groups of related proteins are
shown. The subcellular fraction in which each protein was
principally detected is also indicated.
(DOCX)
Table S2 Details of XME proteins detected in Epiderm-
200. NCBI numbers for each protein and for all members of
groups of related proteins are shown. The subcellular fraction in
which each protein was principally detected is also indicated.
(DOCX)
Table S3 Proteins identified as putative XMEs in
Refseq (version 38) based on a keyword search of
names.
(DOCX)
Table S4 Summary of the proteomic data upon which
protein identifications are based. Each protein or family of
proteins identified is listed in alphabetical order and is accompa-
nied by corresponding NCBI numbers. The subcellular fraction
containing the majority of the peptides for each protein is shown
(microsomal: M or cytosolic: C) as well as the Sf value, which
indicates the certainty of the protein identification in each group of
samples. Details of the peptide sequences and charge upon which
protein identity is based are shown, and the quality of the match of
MS data to these sequences is indicated by Xcorr values that are
shown for each group of samples. A BLAST-type search for each
peptide sequence was performed and where matches to other
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